

## SUBJECT INDEX VOLUME 17

### A

- ACTH
  - ipsapirone, 382
- Adenosine receptors
  - antipsychotic effects, 82
- Adrenocorticotrophic hormone (ACTH). See ACTH
- Affective instability
  - physostigmine effects, 264
- Alpha-methyl-para-tyrosine (AMPT)
  - dopamine effects, 162
- Amperozide
  - effects, 197
- Amphetamines
  - adenosine A<sub>2A</sub> agonists, 82
  - chronic pretreatment effects, 130
- AMPT
  - dopamine effects, 162
- Amygdala
  - neuropeptide Y electrophysiologic actions, 34
- Anticipation
  - schizophrenia, 279
- Antidepressant response
  - sleep deprivation effects on serotonin, 72
- Antidepressants
  - m*-Chlorophenylpiperazine, 341
  - clinical trials, 110, 113
  - fluoxetine effects on sleep EEG, 241
  - response time, 110, 113
  - tricyclic
    - effects, 1
- Antiglucocorticoids
  - effects on 5-HT<sub>1A</sub> function, 246
- Antipsychotics
  - adenosine A<sub>2A</sub> agonists, 82
  - amperozide, 197
  - effects on regional cerebral blood flow, 230
  - MDL 100,907
    - positron emission tomography (PET) study, 175
  - upregulation of D<sub>2</sub>-like receptor subtypes, 186
- Anxiety disorders
  - cholecystokinin (CCK), 360
- AP-1 transcription factor
  - lithium effects, 12
- Aporphines
  - upregulation of D<sub>2</sub>-like receptor subtypes, 186
- Arginine vasopressin
  - major depression, 284
- AtT-20 pituitary cells
  - IL-2 receptor- $\beta$  cDNA clones, 57
- Attention
  - dextroamphetamine effects on brain glucose metabolism, 370
- Autoradiography
  - upregulation of D<sub>2</sub>-like receptor subtypes, 186

### B

Behavioral depression

- chronic amphetamine pretreatment effects, 130
  - Behavioral sensitization
    - chronic amphetamine pretreatment effects, 130
    - schizophrenia, 205
  - Benzodiazepines
    - premenstrual syndrome, 370
  - Bipolar disorder
    - lithium effects, 12
  - Borderline personality disorder
    - cholinergic agents, 264
  - Brain
    - upregulation of D<sub>2</sub>-like receptor subtypes, 186
  - Brain glucose metabolism
    - dextroamphetamine, 370
  - Brain imaging
    - neuropsychiatric disorders, 293
  - Brain radionuclide imaging
    - cocaine withdrawal and striatal 6-FDOPA uptake, 401
- ### C
- C-Fos expression
    - nicotine effects, 151
  - c-Fos immunohistochemistry
    - Y-43611 effects, 27
  - Calcium
    - protein kinase C (PKC) activation, 117
  - Catalepsy
    - adenosine A<sub>2A</sub> agonists, 82
  - Cerebral blood flow
    - regional
      - antipsychotics effects, 230
  - Children
    - fluoxetine effects on sleep EEG, 241
    - m*-Chlorophenylpiperazine
      - depression, 341
  - Cholecystokinin (CCK)
    - anxiety disorders, 360
  - Cholinergic agents
    - borderline personality disorder, 264
  - Chromosome 6
    - schizophrenia, 279
  - Clozapine
    - schizophrenia, 316
    - upregulation of D<sub>2</sub>-like receptor subtypes, 186
  - Cocaine
    - withdrawal and striatal 6-FDOPA uptake, 402
  - Cognition
    - ketamine effects, 141
    - phencyclidine effects, 92
  - Conditioned place preference paradigm
    - oxytocin, 353
  - Corticotropin-releasing factor
    - autoradiographic localization in rat brain, 307
    - distribution of axons across human brainstem nuclei, 325
    - lithium effects, 12
  - Cortisol

- fluoxetine effects, 1
- ipsapirone, 382
- major depression, 284
- menstrual cycle, 100
- Cyclic AMP responsive element. See CRE

### D

- Depression
  - antiglucocorticoids effects on 5-HT<sub>1A</sub> function, 246
  - arginine vasopressin, 284
  - behavioral
    - chronic amphetamine pretreatment effects, 130
  - fluoxetine effects, 1
  - fluoxetine effects on sleep EEG, 241
  - sleep deprivation effects on serotonin, 72
  - sumatriptan effects on serotonergic function, 258
  - tryptophan depletion, 341
- Desensitization
  - regulation of 5-HT<sub>1A</sub> receptor variants, 18
- Dexamethasone
  - menstrual cycle, 100
- Divalproex sodium
  - effects on 5-HT<sub>1A</sub> receptor function, 382
- Dopa analogs and derivatives
  - cocaine withdrawal and striatal 6-FDOPA uptake, 402
- Dopamine
  - amperozide effects, 197
  - dopamine D<sub>2</sub> receptor occupancy, 162
  - phencyclidine effects, 92
  - schizophrenia, 205
- Dopamine D<sub>2</sub> receptors
  - nafadotride effects, 67
  - occupancy by exogenous dopamine, 162
- Dopamine D<sub>3</sub> receptors
  - effects on gene expression in rat forebrain, 27
- Dopamine D<sub>4</sub> receptors
  - effects on gene expression in rat forebrain, 27
- Dopamine D<sub>2</sub>-like receptors
  - effects on gene expression in rat forebrain, 27
- Dopamine metabolism
  - cocaine withdrawal and striatal 6-FDOPA uptake, 402
- Dopamine receptors
  - upregulation of D<sub>2</sub>-like receptor subtypes, 186
- Dorsal hippocampus
  - neuropeptide Y electrophysiologic actions, 34
- Dorsal raphe nucleus
  - risperidone effects, 44
  - sleep deprivation effects on serotonin, 72
- Down-regulation
  - regulation of 5-HT<sub>1A</sub> receptor variants, 18
- Drug abuse
  - glycinergic modulation of phencyclidine (PCP)-induced activity, 202
- Drug withdrawal

chronic amphetamine pretreatment effects, 130  
 Dysphoria  
   borderline personality disorder, 264

## E

EEDQ (N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinolone)  
   nafadotride effects, 67  
 EEG  
   neuropeptide Y electrophysiologic actions, 34  
   sleep  
     fluoxetine effects, 241  
 Electroencephalography (EEG). See EEG  
 Electrophysiology  
   risperidone effects, 44  
 ERPs  
   neuropeptide Y electrophysiologic actions, 34  
 Event-related potentials (ERPs). See ERPs  
 Excitatory amino acids  
   glycinergic modulation of phencyclidine (PCP)-induced activity, 202

## F

[Fluorine-18]fluorodeoxyglucose (FDG)  
   dextroamphetamine effects on brain glucose metabolism, 370  
 Fluoxetine  
   effects, 1  
   effects on sleep EEG, 241  
 Fluphenazine  
   upregulation of D<sub>2</sub>-like receptor subtypes, 186  
 Fos  
   lithium effects, 12  
 Frontal cortex  
   neuropeptide Y electrophysiologic actions, 34  
   risperidone effects, 44

## G

GABA<sub>A</sub>-/benzodiazepine receptor  
   premenstrual syndrome, 370  
 Geller, Edward  
   in memoriam, 350  
 Genes  
   immediate early  
     amperozide effects, 197  
     lithium effects, 12  
     nicotine effects, 151  
 Glucocorticoid receptor  
   menstrual cycle changes, 100  
 Growth hormone  
   effects in depression and mania, 258

## H

Hippocampus  
   chronic amphetamine pretreatment effects, 130  
 Homovanillic acid  
   schizophrenia, 316  
 5-HT<sub>2</sub>  
   MDL 100,907 effects, 175  
 5-HT<sub>2</sub> receptors  
   depression, 341  
 5-HT<sub>1A</sub> autoreceptors  
   sleep deprivation effects on serotonin, 72

5-HT<sub>2A</sub> receptor genes  
   schizophrenia, 274  
 5-HT<sub>1A</sub> receptors  
   divalproex sodium, 382  
   regulation of variants, 18  
 5-HT<sub>1D</sub> receptor agonist  
   serotonergic function in depression or mania, 258  
 L-5-HTP  
   fluoxetine effects, 1  
 Human  
   corticotropin-releasing factor axon distribution across human brainstem nuclei, 325  
   dopamine D<sub>2</sub> receptor occupancy by exogenous dopamine, 162  
   positron emission tomography (PET) study of MDL 100,907, 175  
 5-Hydroxytryptamine. See 5-HT  
 Hypothalamus  
   chronic amphetamine pretreatment effects, 130  
 Hypothermia  
   ipsapirone, 382

## I

[<sup>123</sup>I]IBZM  
   dopamine effects, 162  
 Imaging  
   dextroamphetamine effects on brain glucose metabolism, 370  
 Immediate early genes  
   amperozide effects, 197  
   lithium effects, 12  
   nicotine effects, 151  
 Immunocytochemistry  
   corticotropin-releasing factor axon distribution across human brainstem nuclei, 325  
 In vivo binding  
   dopamine D<sub>2</sub> receptor occupancy by exogenous dopamine, 162  
 In vivo occupancy  
   nafadotride, 67  
 Interleukin-2 receptors  
   IL-2 receptor- $\beta$  cDNA clones, 57  
 Ipsapirone  
   hypothermic, hormonal, and behavioral, 382

## J

Jun  
   lithium effects, 12  
 Jun-B  
   nicotine effects, 151

## K

Ketamine  
   schizophrenia, 141  
 Ketoconazole  
   effects on 5-HT<sub>1A</sub> function, 246

## L

Ligands  
   neuropsychiatric disorders, 293  
 Lithium  
   effects, 12  
 Locomotor activity  
   chronic amphetamine pretreatment effects, 130

Locus coeruleus  
   corticotropin-releasing factor axon distribution across human brainstem nuclei, 325  
 Lymphocytes  
   glucocorticoid receptor effects, 100

## M

Major depressive episode  
   arginine vasopressin, 284  
 Mania  
   sumatriptan effects on serotonergic function, 258  
 MDL 100,907  
   positron emission tomography (PET) study, 175  
 Menstrual cycle  
   glucocorticoid receptor effects, 100  
 Microdialysis  
   chronic amphetamine pretreatment effects, 130  
   risperidone effects, 44  
 Midazolam  
   premenstrual syndrome, 370  
 Molecular cloning  
   IL-2 receptor- $\beta$  cDNA clones, 57  
 mRNA  
   menstrual cycle, 100

## N

N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinolone  
   nafadotride effects, 67  
 N-methyl-D-aspartate (NMDA) receptors.  
   See NMDA receptors  
 Nafadotride  
   effects on D<sub>2</sub> dopamine receptors, 67  
 Negative symptoms  
   glycinergic modulation of phencyclidine (PCP)-induced activity, 202  
 Nemonapride  
   effects on gene expression in rat forebrain, 27  
   upregulation of D<sub>2</sub>-like receptor subtypes, 186  
 Neuroleptic drugs  
   risperidone  
     effects on serotonin output, 44  
 Neuropeptides  
   anxiety disorders, 360  
   neuropeptide Y electrophysiologic actions, 34  
 Neuroplasticity  
   schizophrenia, 205  
 Neuropsychiatric disorders  
   brain imaging, 293  
 Neuroreceptors  
   neuropsychiatric disorders, 293  
 Neuroticism  
   arginine vasopressin, 284  
 Neurotransmitters  
   neuropsychiatric disorders, 293  
 Nicotine  
   effects on Fos expression, 151  
 NMDA receptors  
   glycinergic modulation of phencyclidine (PCP)-induced activity, 202  
   schizophrenia, 141  
 Norepinephrine  
   chronic amphetamine pretreatment effects, 130  
   schizophrenia, 316  
 Nucleus accumbens  
   amperozide effects, 197  
   nicotine effects, 151

**O**

- Obsessive compulsive disorder
  - fluoxetine effects, 1
- Oxytocin
  - conditioned place preference paradigm, 353
  - major depression, 284

**P**

- Pathophysiology
  - schizophrenia, 205
- Phencyclidine
  - effects, 82
  - prefrontal cortex function effects, 92
- Polymorphism
  - regulation of 5-HT<sub>1A</sub> receptor variants, 18
  - schizophrenia, 274, 279
- Positron emission tomography (PET)
  - cocaine withdrawal and striatal 6-FDOPA uptake, 402
  - dextroamphetamine effects on brain glucose metabolism, 370
  - MDL 100,907, 175
  - neuropsychiatric disorders, 293
  - schizophrenia, 230
- Postmortem
  - corticotropin-releasing factor axon distribution across human brainstem nuclei, 325
- Prefrontal cortex
  - phencyclidine effects, 92
- Premenstrual syndrome
  - midazolam, 370
- Progesterone metabolites
  - premenstrual syndrome, 370
- Prolactin
  - fluoxetine effects, 1
- Promoter region
  - schizophrenia, 274
- Psychomimetics
  - phencyclidine, 92
- Psychomotor retardation
  - arginine vasopressin, 284
- Psychosis
  - ketamine effects, 141

**R**

- Raphe
  - corticotropin-releasing factor axon distribution across human brainstem nuclei, 325
- Rats
  - corticotropin-releasing factor localization, 307
  - oxytocin and conditioned place preference paradigm, 353
  - phencyclidine effects, 92
  - Y-43611 effects on forebrain, 27
- Receptor subtype
  - corticotropin-releasing factor localization in rat brain, 307

- Regional cerebral blood flow
  - antipsychotics effects, 230
- Reinforcing
  - conditioned place preference paradigm, 353
- Rodents
  - glycinergic modulation of phencyclidine (PCP)-induced activity, 202

**S**

- S[+]-N-n-propylnorapomorphine
  - upregulation of D<sub>2</sub>-like receptor subtypes, 186
- Saccadic eye velocity
  - premenstrual syndrome, 370
- [<sup>125</sup>I]Savagine
  - corticotropin-releasing factor localization in rat brain, 307
- Schizophrenia
  - adenosine A<sub>2A</sub> agonists, 82
  - antipsychotics effects on regional cerebral blood flow, 230
  - clozapine, 316
  - dopamine effects, 162
  - glycinergic modulation of phencyclidine (PCP)-induced activity, 202
  - 5-HT<sub>2A</sub> receptor gene, 274
  - pathophysiology, 205
  - phencyclidine effects, 92
  - trinucleotide repeat clones, 279
- Second messenger
  - protein kinase C (PKC) activation, 117
- Sedation
  - premenstrual syndrome, 370
- Serotonin
  - amperozide effects, 197
  - antiglucocorticoids effects, 246
  - anxiety disorders, 360
  - depression, 341
  - divalproex sodium, 381
  - fluoxetine effects, 1
  - protein kinase C (PKC) activation, 117
  - regulation of 5-HT<sub>1A</sub> receptor variants, 18
  - risperidone effects, 44
  - sleep deprivation effects, 72
- Serotonin<sub>2A/2C</sub>
  - protein kinase C (PKC) activation, 117
- Signal transduction
  - IL-2 receptor-β cDNA clones, 57
- Single photon emission computed tomography (PET)
  - neuropsychiatric disorders, 293
- Single-stranded conformation
  - polymorphism
  - schizophrenia, 274
- Sleep deprivation
  - effects on serotonin, 72
- Sleep EEG
  - fluoxetine effects, 241
- Spectral analysis
  - neuropeptide Y electrophysiologic actions, 34

- neuropeptide Y electrophysiologic actions, 34
- Spiroperone
  - upregulation of D<sub>2</sub>-like receptor subtypes, 186
- Stimulants
  - brain glucose metabolism, 370
  - cocaine withdrawal and striatal 6-FDOPA uptake, 402
- Stress
  - corticotropin-releasing factor localization in rat brain, 307
- Striatal 6-FDOPA uptake
  - cocaine withdrawal, 402
- Striatum
  - amperozide effects, 197
  - dopamine D<sub>2</sub> receptor occupancy by exogenous dopamine, 162
  - nafadotride effects, 67
- Sumatriptan
  - serotonergic function in depression or mania, 258
- [<sup>3</sup>H]Spiroperone nafadotride effects, 67
- Symptomatology
  - schizophrenia, 316

**T**

- Transporter
  - protein kinase C (PKC) activation, 117
- Tricyclic antidepressants
  - effects, 1
- Trinucleotide repeat clones
  - schizophrenia, 279
- Tryptophan
  - depression, 341

**U**

- Utilization
  - phencyclidine effects, 92

**V**

- Ventral mesencephalon
  - corticotropin-releasing factor axon distribution across human brainstem nuclei, 325

**W**

- Working memory
  - phencyclidine effects, 92

**Y**

- Y-43611
  - effects on gene expression in rat forebrain, 27